Technical Analysis for RNXT - RenovoRx, Inc.

Grade Last Price % Change Price Change
D 6.52 -7.12% -0.50
RNXT closed up 0.07 percent on Monday, September 27, 2021, on 10 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical RNXT trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup -6.04%
Narrow Range Bar Range Contraction -6.04%
Wide Bands Range Expansion -6.04%
Oversold Stochastic Weakness -6.04%
New 52 Week Closing Low Bearish -5.97%
Hot IPO Pullback Bullish Swing Setup -5.97%
Narrow Range Bar Range Contraction -5.97%
Wide Bands Range Expansion -5.97%
Oversold Stochastic Weakness -5.97%
Stochastic Buy Signal Bullish -10.50%
Older End-of-Day Signals for RNXT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 1 hour ago
New 52 Week Low about 1 hour ago
60 Minute Opening Range Breakdown about 4 hours ago
Down 3% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatments Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Gemcitabine Evofosfamide

Is RNXT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.74
52 Week Low 6.66
Average Volume 3,460,369
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 8.69
10-Day Moving Average 7.53
Average True Range 1.62
ADX 0.0
+DI 25.75
-DI 13.09
Chandelier Exit (Long, 3 ATRs) 11.87
Chandelier Exit (Short, 3 ATRs) 11.53
Upper Bollinger Bands 12.55
Lower Bollinger Band 4.83
Percent B (%b) 0.28
BandWidth 88.73
MACD Line -0.83
MACD Signal Line -0.58
MACD Histogram -0.255
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.80
Resistance 3 (R3) 7.83 7.59 7.67
Resistance 2 (R2) 7.59 7.39 7.58 7.63
Resistance 1 (R1) 7.31 7.27 7.45 7.28 7.58
Pivot Point 7.07 7.07 7.15 7.06 7.07
Support 1 (S1) 6.79 6.87 6.93 6.76 6.46
Support 2 (S2) 6.55 6.75 6.54 6.41
Support 3 (S3) 6.27 6.55 6.37
Support 4 (S4) 6.24